NEWM&A

Soleno Therapeutics (SLNO) Stock Rating Cut Following Acquisition Deal

Published on 4/7/2026

#SLNO#M&A#Stifel
Soleno Therapeutics (SLNO) Stock Rating Cut Following Acquisition Deal

AI Summary

Stifel reduced the stock rating for Soleno Therapeutics (SLNO) amid news of its acquisition deal, although specific financial details of the deal were not disclosed. The adjustment indicates a cautious outlook on SLNO's performance following the announcement. Acquisition deals often impact stock values due to shifts in operational focus and investor sentiment. How this will affect the future market performance of Soleno remains to be seen.

Source: Read original article (opens in new tab)

Related News

Universal Music (UMG) Stocks Up 10% After $64 Billion Proposal
M&A

Universal Music (UMG) Stocks Up 10% After $64 Billion Proposal

Apr 7

Ford (F) recalls 420,000 vehicles in US for wiper failure issue
M&A

Ford (F) recalls 420,000 vehicles in US for wiper failure issue

Apr 7

Pershing Square Offers €55bn for Universal Music Group Acquisition
M&A

Pershing Square Offers €55bn for Universal Music Group Acquisition

Apr 7

Pershing Square Offers $65 Billion for Universal Music (UMG)
M&A

Pershing Square Offers $65 Billion for Universal Music (UMG)

Apr 7